pharmaphorum

APRIL 7, 2021

It’s also set for a slice of income from Tepezza (teprotumumab), a drug it developed with Horizon that was launched last year to treat active thyroid disease and generated 298 million DKK ($47m) in 2020. There’s potential for combination drugs, paving the way for less toxic chemotherapy-free cancer drugs.

Chemotherapy

pharmaphorum

APRIL 16, 2021

GSK decided to stop enrolling patients on the phase 2 INDUCE-3 trial, discontinuing treatment with feladilimab and has also axed the INDUCE-4 phase 2 trial, testing feladilimab versus placebo in combination with Keytruda and chemotherapy. billion signed with Germany’s Merck KGaA.

Chemotherapy

Pharmaceutical Technology

JANUARY 30, 2023

In a Complete Response Letter to Eli Lilly in March 2022, the FDA indicated that the Oncologic Drug Advisory Committee voted overwhelmingly in favour of requiring more research to support the approval of sintilimab with pemetrexed and platinum-based chemotherapy for nonsquamous non-small cell lung cancer.

FDA

Pharmaceutical Technology

JULY 23, 2008

With expensive new treatments, increasing numbers of patients in chemotherapy in major markets and developing nations like China, Brazil and Russia investing more in treating and diagnosing cancer, IMS predicts a compound growth rate of 12–15% and tips the global market to reach $80bn by 2012. We’re on the right path.”

Pharmaceutical Companies

pharmaphorum

NOVEMBER 24, 2020

As lockdowns started in the West during March 2020, there was, inevitably, much punditry on exit scenarios – for economies, populations, and healthcare systems. Even past the second wave, as vaccines become available, healthcare systems will not return rapidly to pre-pandemic capacities, let alone deliver more than that capacity.

Pharmaceutical Companies

pharmaphorum

MARCH 15, 2021

A phase 3 trial of the PD-1 inhibitor in cervical cancer patients who had progressed after first-line chemotherapy has been stopped early after an interim look at the data showed that the drug cut mortality by 31% compared to second-line chemo. billion, though still well shy of the $14 billion-plus posted by class leader Keytruda in 2020.

Chemotherapy

European Pharmaceutical Review

JULY 26, 2022

The CHMP also recommended an extension of the use of the smallpox vaccine Imvanex (live modified vaccinia virus Ankara) to include protecting adults from monkeypox and disease caused by vaccinia virus. Veklury received a conditional marketing authorisation in July 2020, which was last renewed in March 2022. Rubraca referral outcome.

Vaccines

pharmaphorum

NOVEMBER 14, 2022

The narrower label for Zejula (niraparib) means it can only be used as second-line maintenance therapy after platinum-based chemotherapy in patients with these cancers whose tumours carry a germline BRCA mutation – around 15% of the population. That was due last Friday, but cancelled when GSK opted to withdraw the approval.

Labelling

Pharmaceutical Technology

AUGUST 1, 2022

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.

Vaccines

STAT

MARCH 6, 2023

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine.

Vaccines

The Checkup by Singlecare

AUGUST 3, 2023

There were nearly 10 million cancer deaths in 2020 around the world. ( WHO , 2022) In 2020, there were around 18.1 WCRF , 2022) In 2020, more than 1.6 CDC , 2023) In 2020, there were more than 602,000 cancer deaths in the U.S. ( WCRF , 2022) In 2020, there were around 9.3 WCRF , 2022) In 2020, there were around 9.3

Chemotherapy